Pfizer receives positive CHMP opinion for oncology biosimilar RUXIENCE

This article was originally published here

RUXIENCE is a monoclonal antibody (mAb) for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA),

The post Pfizer receives positive CHMP opinion for oncology biosimilar RUXIENCE appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply